29 Mar 2022 Avacta to present pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting Investors | Therapeutics
03 Feb 2022 Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin Investors | Therapeutics
18 Jan 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Investors | Therapeutics
10 Jan 2022 Update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant Diagnostics | Investors
22 Dec 2021 AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing Diagnostics | Investors